
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
Yuan Liu, Yufeng Cheng, Yong Xu, et al.
Oncogene (2017) Vol. 36, Iss. 44, pp. 6143-6153
Open Access | Times Cited: 313
Yuan Liu, Yufeng Cheng, Yong Xu, et al.
Oncogene (2017) Vol. 36, Iss. 44, pp. 6143-6153
Open Access | Times Cited: 313
Showing 1-25 of 313 citing articles:
Comprehensive review of targeted therapy for colorectal cancer
Yuanhong Xie, Yingxuan Chen, Jing‐Yuan Fang
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1316
Yuanhong Xie, Yingxuan Chen, Jing‐Yuan Fang
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1316
Exploring the NK cell platform for cancer immunotherapy
Jacob A. Myers, Jeffrey S. Miller
Nature Reviews Clinical Oncology (2020) Vol. 18, Iss. 2, pp. 85-100
Open Access | Times Cited: 920
Jacob A. Myers, Jeffrey S. Miller
Nature Reviews Clinical Oncology (2020) Vol. 18, Iss. 2, pp. 85-100
Open Access | Times Cited: 920
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Joy Hsu, Jonathan J. Hodgins, Malvika Marathe, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 10, pp. 4654-4668
Open Access | Times Cited: 665
Joy Hsu, Jonathan J. Hodgins, Malvika Marathe, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 10, pp. 4654-4668
Open Access | Times Cited: 665
Natural killer cells in cancer biology and therapy
Song‐Yang Wu, Tong‐Ming Fu, Yi‐Zhou Jiang, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 626
Song‐Yang Wu, Tong‐Ming Fu, Yi‐Zhou Jiang, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 626
Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Giuseppe Lo Russo, Massimo Moro, Michele Sommariva, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 3, pp. 989-999
Open Access | Times Cited: 370
Giuseppe Lo Russo, Massimo Moro, Michele Sommariva, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 3, pp. 989-999
Open Access | Times Cited: 370
Tumor-Infiltrating Natural Killer Cells
Beatriz Cózar, Marco Greppi, Sabrina Carpentier, et al.
Cancer Discovery (2020) Vol. 11, Iss. 1, pp. 34-44
Open Access | Times Cited: 354
Beatriz Cózar, Marco Greppi, Sabrina Carpentier, et al.
Cancer Discovery (2020) Vol. 11, Iss. 1, pp. 34-44
Open Access | Times Cited: 354
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
Ombretta Melaiu, Valeria Lucarini, Loredana Cifaldi, et al.
Frontiers in Immunology (2020) Vol. 10
Open Access | Times Cited: 339
Ombretta Melaiu, Valeria Lucarini, Loredana Cifaldi, et al.
Frontiers in Immunology (2020) Vol. 10
Open Access | Times Cited: 339
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Romain Donné, Amaia Lujambio
Hepatology (2022) Vol. 77, Iss. 5, pp. 1773-1796
Closed Access | Times Cited: 327
Romain Donné, Amaia Lujambio
Hepatology (2022) Vol. 77, Iss. 5, pp. 1773-1796
Closed Access | Times Cited: 327
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Natalie K. Wolf, Djem Kissiov, David H. Raulet
Nature reviews. Immunology (2022) Vol. 23, Iss. 2, pp. 90-105
Closed Access | Times Cited: 301
Natalie K. Wolf, Djem Kissiov, David H. Raulet
Nature reviews. Immunology (2022) Vol. 23, Iss. 2, pp. 90-105
Closed Access | Times Cited: 301
NK Cell-Based Immune Checkpoint Inhibition
Muhammad Khan, Sumbal Arooj, Hua Wang
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 277
Muhammad Khan, Sumbal Arooj, Hua Wang
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 277
The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector
Wenjuan Dong, Xiaojin Wu, Shoubao Ma, et al.
Cancer Discovery (2019) Vol. 9, Iss. 10, pp. 1422-1437
Open Access | Times Cited: 252
Wenjuan Dong, Xiaojin Wu, Shoubao Ma, et al.
Cancer Discovery (2019) Vol. 9, Iss. 10, pp. 1422-1437
Open Access | Times Cited: 252
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Michal A. Stanczak, Shoib Sarwar Siddiqui, Marcel P. Trefny, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 11, pp. 4912-4923
Open Access | Times Cited: 247
Michal A. Stanczak, Shoib Sarwar Siddiqui, Marcel P. Trefny, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 11, pp. 4912-4923
Open Access | Times Cited: 247
PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
Neda Yaghoubi, Arash Soltani, Kiarash Ghazvini, et al.
Biomedicine & Pharmacotherapy (2018) Vol. 110, pp. 312-318
Open Access | Times Cited: 247
Neda Yaghoubi, Arash Soltani, Kiarash Ghazvini, et al.
Biomedicine & Pharmacotherapy (2018) Vol. 110, pp. 312-318
Open Access | Times Cited: 247
NK cells and ILCs in tumor immunotherapy
Simona Sivori, Daniela Pende, Linda Quatrini, et al.
Molecular Aspects of Medicine (2020) Vol. 80, pp. 100870-100870
Open Access | Times Cited: 197
Simona Sivori, Daniela Pende, Linda Quatrini, et al.
Molecular Aspects of Medicine (2020) Vol. 80, pp. 100870-100870
Open Access | Times Cited: 197
Advances and challenges in the treatment of esophageal cancer
Shiming He, Jian Xu, Xiujun Liu, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 11, Iss. 11, pp. 3379-3392
Open Access | Times Cited: 186
Shiming He, Jian Xu, Xiujun Liu, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 11, Iss. 11, pp. 3379-3392
Open Access | Times Cited: 186
Killers 2.0: NK cell therapies at the forefront of cancer control
Jonathan J. Hodgins, S. Khan, Maria M. Park, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 9, pp. 3499-3510
Open Access | Times Cited: 185
Jonathan J. Hodgins, S. Khan, Maria M. Park, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 9, pp. 3499-3510
Open Access | Times Cited: 185
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
Takashi Nakamura, Takanori Sato, Rikito Endo, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 7, pp. e002852-e002852
Open Access | Times Cited: 184
Takashi Nakamura, Takanori Sato, Rikito Endo, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 7, pp. e002852-e002852
Open Access | Times Cited: 184
Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment
Sophie M. Poznanski, Kanwaldeep Singh, Tyrah M. Ritchie, et al.
Cell Metabolism (2021) Vol. 33, Iss. 6, pp. 1205-1220.e5
Open Access | Times Cited: 180
Sophie M. Poznanski, Kanwaldeep Singh, Tyrah M. Ritchie, et al.
Cell Metabolism (2021) Vol. 33, Iss. 6, pp. 1205-1220.e5
Open Access | Times Cited: 180
Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
Julie Giraud, Domitille Chalopin, Jean‐Frédéric Blanc, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 173
Julie Giraud, Domitille Chalopin, Jean‐Frédéric Blanc, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 173
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
Silvia Pesce, Marco Greppi, Francesco Grossi, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 156
Silvia Pesce, Marco Greppi, Francesco Grossi, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 156
Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
Gaurav Nayyar, Yaya Chu, Mitchell S. Cairo
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 147
Gaurav Nayyar, Yaya Chu, Mitchell S. Cairo
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 147
The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
Lingyu Tian, Daniel J. Smit, Manfred Jücker
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2652-2652
Open Access | Times Cited: 123
Lingyu Tian, Daniel J. Smit, Manfred Jücker
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2652-2652
Open Access | Times Cited: 123
Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy
Ziyi Bai, Yao Zhou, Zifan Ye, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 119
Ziyi Bai, Yao Zhou, Zifan Ye, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 119
Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options
Zuzanna Sas, Ewa Cendrowicz, Isabel Weinhäuser, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3778-3778
Open Access | Times Cited: 118
Zuzanna Sas, Ewa Cendrowicz, Isabel Weinhäuser, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3778-3778
Open Access | Times Cited: 118
Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy
Qin Qiu, Yuqi Lin, Yucui Ma, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 107
Qin Qiu, Yuqi Lin, Yucui Ma, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 107